Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial
1. 系统已在2026-09-24 10:09:48对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1038/s41591-026-04559-4
文献链接: https://www.nature.com/articles/s41591-026-04559-4
其他信息:
出版社: Springer Science and Business Media LLC
作者: Xinghao Ai; Zhengbo Song; Lin Wu; Aiping Zhou; Di Cheng; Hong Zong; Heshui Wu; Zuoxing Niu; Yuping Sun; Lingjun Zhu; Zhiwei Li; Yanhong Deng; Ying Yuan; Xiujuan Qu; Haitao Zhao; Yingying Du; Ziming Li; Yu Wang; Haige Shen; Huaqiang Zhu; Chanli Zheng; Shuang Wang; Zhao Cui; Lingyu Tai; Shun Lu
全文下载地址: https://www.nature.com/articles/s41591-026-04559-4.pdf

